The antifungal activity of orally active SM-4470, (R)-3-(n-butylthio)-2-(2,4-dichlorophenyl)-1-(imidazole-1-yl)-Z-propanol hydrochloride, was compared with that of ketoconazole. SM-4470 showed twofold-higher activity than ketoconazole in the oral treatment of systemic infection with Candida albicans in mice. In addition, SM-4470 was effective against aspergillosis in mice, but ketoconazole was ineffective. The efficacy of SM-4470 was similar to that of ketoconazole in curing experimental candidal vaginitis in rats and trichophytosis in guinea pigs, although its serum concentrations in these animals were lower than those of ketoconazole. These data suggest that SM-4470 may be of value in the treatment of both systemic and superficial fungal infections in humans.
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Several new imidazole and triazole antifungal agents have been developed in the last few years. These are effective topically in the treatment of dermatophytosis and vaginal candidiasis, but ketoconazole is the only commercially available imidazole that is orally effective against these infections (3) (4) (5) . Ketoconazole has shown variable activity against life-threatening systemic infections (3); the polyene amphotericin B is still used for treating these infections, but its use is limited by toxicity and the need to give it by intravenous infusion. The other agent of significance is 5-fluorocytosine, which has a limited spectrum of antifungal activity, and its use in therapy frequently leads to the emergence of resistant strains. We recently succeeded in developing SM-4470 (Fig. 1) , a new imidazole derivative. In this report we compare its activity with that of ketoconazole against experimental systemic and superficial infections in laboratory animals.
MATERIALS AND METHODS
Fungi. All fungi used in these studies were from the culture collection in our laboratory. Cultures of these organisms were freeze-dried and stored, and subcultures on Sabouraud dextrose agar (SDA) were made as needed. Candida albicans and Aspergillus fumigatus strains were grown at 30°C on SDA with 5% rabbit blood for 3 days, and respectively. These animals were also used in pharmacokinetic studies. Animals were maintained in airconditioned rooms at 20 to 24°C and were allowed food and water ad libitum. Systemic infections in mice. Acute infections in mice were produced by injection (via the lateral tail vein) of salinewashed blastospores of C. albicans or A. fumigatus. Each inoculum was uniformly lethal for control animals within 3 to 5 days. Groups of 10 animals received either SM-4470 (dose range, 12.5 to 200 mg/kg) or ketoconazole (dose range, 12.5 to 200 mg/kg). Appropriate doses (0.1 ml/10 g of body weight) were administered by gavage as a suspension in 0.5% methylcellulose at 0 and 5 h after infection. In the Aspergillus infection, three mice from each treatment group, at the dose of 50 mg/kg, and three infected control mice were sacrificed 24 h after infection. Lungs were removed, weighed, and homogenized in saline. Serial 10-fold dilutions of the homogenate were plated on SDA plates and incubated at 37°C for 48 h. The number of viable Aspergillus cells per gram of lung tissue was calculated (6) . The 50% effective dose (ED50) was calculated with Probit analysis by fitting survival data for each group at the time when all the control mice were dead (10).
Vaginal infection with C. albicans in rats. Vaginal infection with C. albicans was induced as described by Thienpoint et al. (11) . Female Wistar rats were ovarectomized and maintained in permanent estrus by subcutaneous injection of estradiol benzoate (1 mg per rat) once weekly for 3 weeks. The animals were then infected intravaginally with 107 cells assigned to different treatment groups. Therapy by gavage was started on day 3 after infection and was continued once daily for four consecutive days. Groups of animals received treatment with either SM-4470 at 5 or 25 mg/kg or ketoconazole at 5 or 25 mg/kg. Mycological data were used in assessing the efficacy of treatment. Mycological response was estimated by recovery of viable T. mentagrophytes cells in cultured skin samples. Cultures were incubated for 7 days on SDA containing 0.04% cycloheximide and 0.005% chloramphenicol at 30°C. Mycological efficacy data in this paper were taken on day 7 after infection, because at this time 100% of the cultures were positive for nontreated animals, and the lower limit of sensitivity of detection in this study was 50 CFU of dermatophytes per g of skin. Serum concentrations in mice, rats, and guinea pigs. All animals were fasted for 18 h before and for the duration of each experiment. Water was freely available at all times. SM-4470 or ketoconazole was administered by gavage at a dose level of 100 mg/kg of body weight. Blood specimens were obtained from the axillary and abdominal arteries of mice, rats, and guinea pigs that had been anesthetized with ethyl ether at each sampling time. Serum was separated by centrifugation at 2,000 x g for 15 min at 4°C.
Concentrations in serum were assayed by the paper disk method with C. albicans SP-2331 (a clinical isolate) in yeast morphology agar (Difco Laboratories). The sensitivity of this method was about 0.3 ,ug/ml. The drug concentrations in serum were calculated from the standard curves of the drugs dissolved in normal serum from the respective animals.
RESULTS
Systemic infections in mice. The protective activity of SM-4470 administered orally to mice infected with C. albicans is summarized in Table 1 . SM-4470 was approximately twofold more potent than ketoconazole against this infection in mice. SM-4470 was more potent than ketoconazole in both strain ddY and ICR mice and also against both C. albicans isolates. In addition, SM-4470 was effective against systemic infections with two strains of A. fumigatus, but ketoconazole had no activity against either strain (Table 2) . For example, when orally administered at a dose of 50 mg/kg, the survival rate at day 10 after infection of mice treated with SM-4470 and ketoconazole was 5 of 10 and 0 of 10, respectively (P < 0.05 by Fisher's exact test). Table 2 also shows that 1039 Aspergillus cells per gram of lung tissue were recovered from untreated control mice at 24 h after infection. SM-4470 also significantly reduced the number of viable cells recoverable from the lung compared to ketoconazole.
Vaginal infection with C. albicans in rats. At least 97% of the untreated rats were infected with C. albicans when assessed mycologically 7 days after infection (Table 3) .
SM-4470 was curative in this model when given orally as one dose on four consecutive days starting 3 days after the infection. It had the same activity as ketoconazole in this model. Guinea pig dermatophytosis. Animals infected with T. mentagrophytes developed skin infection. SM-4470 was slightly but not significantly more active than ketoconazole (Table 4) .
Concentrations in serum. The concentrations of SM-4470 and ketoconazole in the sera of mice, rats, and guinea pigs given a single oral dose of 100 mg/kg are shown in Table 5 . The serum concentrations of SM-4470 were significantly lower than those of ketoconazole in all animals. There were especially striking differences between SM-4470 and ketoconazole in rats. The peak serum levels of SM-4470 were threefold lower in mice and guinea pigs and 20-fold lower in rats than those of ketoconazole.
DISCUSSION
Human fungal diseases can be divided into life-threatening systemic infections and the more common superficial ones. Systemic mycoses in the compromised host, especially in patients undergoing immunosuppressive or cancer therapy, are an increasing problem (5, 12) , and the few drugs currently available have limited efficacy or are poorly tolerated (1) .
In the present study, SM-4470 showed several advantages over currently used systemic agents. It exerted possibly more active protection than ketoconazole by oral treatment in mice with lethal C. albicans and A. fumigatus infections, which are common causes of fungal infection in immunosuppressed patients.
The most common superficial infections are dermatophytosis and vaginal candidiasis. Although many topical preparations are available, they are frequently inconvenient to use; there is therefore a need for a safe, orally effective agent. In this model of vaginal candidiasis in rats, SM-4470 showed activity similar to that of ketoconazole.
Trichophytosis in guinea pigs is a well-established predictive model for testing topical (5, 7, 8) and systemic antifungal agents (2, 3, 9) . Published 265B, 1983) . Therefore, SM-4470 showed as same activity as or possibly higher activity than ketoconazole in these experimental fungal infections. In addition, SM-4470 has a toxicity similar to that of ketoconazole (unpublished data), and it seems to have a wider spectrum of antifungal action than not only ketoconazole but also 5-fluorocytosine and griseofulvin. This activity profile suggests that SM-4470 may have potential for therapy of human fungal infections.
